In Phase A, participants will obtain distinctive doses and schedules of oral ABBV-744 tablet to discover safe dosing program. Further members will probably be enrolled for the discovered monotherapy dosign regimen. In Segment B, individuals will obtain oral ruxolitinib and ABBV-744 are going to be specified as "add-on" therapy. In https://abbv-744forsmallcelllungc24578.win-blog.com/12312492/rumored-buzz-on-abbv-744-for-small-cell-lung-cancer-research